CN1751052A - 治疗药物 - Google Patents

治疗药物 Download PDF

Info

Publication number
CN1751052A
CN1751052A CNA2003801098327A CN200380109832A CN1751052A CN 1751052 A CN1751052 A CN 1751052A CN A2003801098327 A CNA2003801098327 A CN A2003801098327A CN 200380109832 A CN200380109832 A CN 200380109832A CN 1751052 A CN1751052 A CN 1751052A
Authority
CN
China
Prior art keywords
alkyl
amino
carbamoyl
group
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801098327A
Other languages
English (en)
Chinese (zh)
Inventor
R·W·A·卢克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1751052A publication Critical patent/CN1751052A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2003801098327A 2002-12-24 2003-12-19 治疗药物 Pending CN1751052A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0230089.5A GB0230089D0 (en) 2002-12-24 2002-12-24 Therapeutic agents
GB0230089.5 2002-12-24

Publications (1)

Publication Number Publication Date
CN1751052A true CN1751052A (zh) 2006-03-22

Family

ID=9950374

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801098327A Pending CN1751052A (zh) 2002-12-24 2003-12-19 治疗药物

Country Status (16)

Country Link
US (1) US20060069109A1 (enExample)
EP (1) EP1575963B1 (enExample)
JP (1) JP2006515593A (enExample)
KR (1) KR20050087852A (enExample)
CN (1) CN1751052A (enExample)
AT (1) ATE394403T1 (enExample)
AU (1) AU2003295135A1 (enExample)
BR (1) BR0317708A (enExample)
CA (1) CA2508917A1 (enExample)
DE (1) DE60320849D1 (enExample)
ES (1) ES2305548T3 (enExample)
GB (1) GB0230089D0 (enExample)
MX (1) MXPA05006921A (enExample)
NO (1) NO20052989L (enExample)
WO (1) WO2004058776A1 (enExample)
ZA (1) ZA200504827B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
SI1973545T1 (sl) * 2005-12-23 2013-04-30 Ariad Pharmaceuticals, Inc. Spojine bicikličnega heteroarila
ES2761180T3 (es) * 2005-12-23 2020-05-19 Ariad Pharma Inc Compuestos bicíclicos de heteroarilo
AU2015210454B2 (en) * 2005-12-23 2016-10-27 Takeda Pharmaceuticals U.S.A., Inc. Bicyclic heteroaryl compounds
US8278307B2 (en) 2006-05-08 2012-10-02 Ariad Pharmaceuticals, Inc. Monocyclic Heteroaryl compounds
WO2007133560A2 (en) 2006-05-08 2007-11-22 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
EP2120964A2 (en) 2006-12-15 2009-11-25 Abraxis BioScience, Inc. Triazine derivatives and their therapeutical applications
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
JP2012529517A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
KR101457027B1 (ko) 2009-06-09 2014-10-31 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
BR112014028006A2 (pt) * 2012-05-30 2017-06-27 Hoffmann La Roche heterociclos de pirrolidino
CA3167093A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
DK4013502T3 (da) * 2019-08-16 2025-11-10 Cyclacel Pharmaceuticals Inc Fremgangsmåde til fremstillingen af et pyrimidino-diazepinderivat

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517758A (en) * 1999-09-17 2004-06-25 Abbott Gmbh & Co Pyrazolopyrimidines useful as therapeutic agents
KR20020050294A (ko) * 1999-11-22 2002-06-26 피터 기딩스 신규화합물
EP1343779B1 (en) * 2000-11-20 2007-06-27 Smithkline Beecham Corporation Novel compounds
DE60304718T2 (de) * 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität

Also Published As

Publication number Publication date
ZA200504827B (en) 2006-04-26
CA2508917A1 (en) 2004-07-15
EP1575963B1 (en) 2008-05-07
BR0317708A (pt) 2005-11-22
US20060069109A1 (en) 2006-03-30
JP2006515593A (ja) 2006-06-01
AU2003295135A1 (en) 2004-07-22
KR20050087852A (ko) 2005-08-31
EP1575963A1 (en) 2005-09-21
NO20052989L (no) 2005-07-21
ATE394403T1 (de) 2008-05-15
DE60320849D1 (de) 2008-06-19
ES2305548T3 (es) 2008-11-01
MXPA05006921A (es) 2005-08-18
NO20052989D0 (no) 2005-06-17
WO2004058776A1 (en) 2004-07-15
GB0230089D0 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
CN1269813C (zh) 作为细胞增生抑制剂的咪唑－5－基－2－苯胺基－嘧啶
CN1161352C (zh) 喹唑啉衍生物
CN1240688C (zh) 喹唑啉化合物
CN1252065C (zh) 噌啉化合物
CN1245402C (zh) 吲哚衍生物、其制备方法、含有它们的药物组合物及其用途
CN1751052A (zh) 治疗药物
CN1114598C (zh) 芳族化合物和含有它们的药物组合物
CN1993349A (zh) 作为erbb受体酪氨酸激酶的喹唑啉衍生物
CN1882580A (zh) 作为抗增殖药物的喹唑啉衍生物
CN1625555A (zh) 喹唑啉化合物
CN1585754A (zh) 用作抗肿瘤药物的喹唑啉衍生物
CN1649863A (zh) 具有cdk抑制活性的4－(咪唑－5－基)－2－(4－磺基苯胺基)嘧啶衍生物
CN1681508A (zh) 新型激酶抑制剂
CN100343254C (zh) 吡咯并嘧啶衍生物
CN1642922A (zh) 具有抗癌活性的取代的吲唑
CN1882573A (zh) 作为酪氨酸激酶抑制剂的喹唑啉衍生物
CN1898216A (zh) 酰胺衍生物
CN1914182A (zh) 喹唑啉衍生物
CN1218801A (zh) 三取代咪唑类化合物、其制备方法与用途以及含有它们的药物组合物
CN1391563A (zh) 治疗用喹唑啉衍生物
CN1922182A (zh) 作为激酶抑制剂的吡咯并三嗪化合物
CN1863779A (zh) 新型吲唑衍生物
CN1711264A (zh) 具有抗癌活性的嘧啶并[4,5－d]嘧啶衍生物
CN1446212A (zh) 具有vegf抑制活性的喹啉衍生物
CN1127486C (zh) 二氮杂萘衍生物磷酸二酯酶4抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060322